Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

The Society of Chemical Manufacturers and Affiliates (SOCMA), in a statement submitted to the US House Subcommittee on Cybersecurity, Infrastructure Protection and Security Technologies, called for Congressional action to pass a three-to-five year authorization of current Chemical Facility Anti-Terrorism Standards (CFATS), which are scheduled to expire Mar. 4, 2011.

SOCMA Urges Congressional Action on Chemical-Site Security Standards

Gilead to Acquire Calistoga; Bayer Healthcare Appoints Former Pfizer Exec; and More.

Week of Feb. 21, 2011: Company and People Notes: Gilead to Acquire Calistoga; Bayer Healthcare Appoints Former Pfizer Exec; and More.

Company and People Notes: sanofi to Acquire Genzyme; Lilly Makes Senior Appointments; and More.

Week of Feb. 14, 2011: Company and People Notes: sanofi to Acquire Genzyme; Lilly Makes Senior Appointments; and More.

Pfizer Acquires Ferrosan's Consumer Health Business; Patheon Appoints Former Biogen Exec as CEO; and More.

Week of Feb. 7, 2011: Company and People Notes: Pfizer Acquires Ferrosan's Consumer Health Business; Patheon Appoints Former Biogen Exec as CEO; and More.

The Society of Chemical Manufacturers and Affiliates (SOCMA), in a statement submitted to the US Senate Subcommittee on Superfund, Toxic and Environmental Health, provided support for a bipartisan review of the Toxic Substances Control Act (TSCA) as that subcommittee considers reforming the  chemical control law.

SOCMA Issues Statement to US Senate Subcommittee on TSCA Reform

Company and People Notes: Pfizer Completes King Tender Offer; Cook Pharmica Names VP of R&D and CSO; and More

Week of Jan. 31, 2011: Company and People Notes: Pfizer Completes King Tender Offer; Cook Pharmica Names VP of R&D and CSO; and More.

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Follow-ons were all the rage at this year's JP Morgan Healthcare Conference.

Follow-Ons: The New Black?

Will 2011 be a more promising year for new molecular entities? A review of Big Pharma's late-stage pipeline shows what might lie ahead.

Evaluating Late-Stage Pipelines and Potential

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Report from India

Q&A with Magnetrol International's Dan Klees

Ingredients